Replies to post #74170 on Biotech Values

[ThomasS]

MNTA: Nice find! Just so happens I increased my MNTA position Friday, expecting "a decision" sooner than later...

[gophie]

MNTA So, what's new? It's the same pitch...coming from Wheeler and someone who wants his business.

[charmed1]

Dew...The best part is the quote from CEO Craig Wheeler about ¾ of the way down.]
You are kidding right??

[tinkershaw]

Lovenox is Sanofi’s biggest product. The Paris-based drugmaker has urged the FDA to reject generics of that medicine, because the Lovenox molecule isn’t “fully characterized” and can’t be duplicated. Teva says the same thing about Copaxone, which generated $2.26 billion in 2008.‹

Just going back through the ReadmeFirst page and looking at some articles. I find the above quite illustrative given the historical context that we can now see it in, as this article is from a March 10, 2009 article that is 1.25 years from actual menoxaparin approval.

What seems the most likely outcome is that all the TEVA statements that are nearly identical to the Sanofi statement in bold above will probably end up in an identical outcome, of the statements being PR with little substance behind it. If the copaxone litigation can be ended on a positive footing, one has to like the present circumstances.

But, from a historical context, I doubt, back in March of 2009 when this story was published, that if you were told that menoxaparin would be approved in July of 2010, and remain the only approved generic through the middle of January 2011, and still going, that anyone here, ANYONE, would have even hazarded a guess that the share price would be $16.50 a share, much less with the cash balance that is being created. Even if you were told that M118 might go down with no value. So these historical contexts work both ways.

Copaxone does not have the same contractual issues, there is just the uncertainty of when it will be approved, and when it can go to market (assuming it won't be launched at risk - but it might at that pending the result at trial).

I would really like to see what FoB MNTA has in mind.

Anyone know the sort of time frame to market that MNTA is anticipating with their FoB program? I don't recall seeing any color as to any estimates of what the company expects in regard to time frames. It is just one of those things that they are working on and will happen in the future.

Tinker